Welcome to our dedicated page for Puretech Health news (Ticker: PRTC), a resource for investors and traders seeking the latest updates and insights on Puretech Health stock.
PureTech Health plc (symbol: PRTC) is a cutting-edge biotechnology company committed to developing and commercializing innovative medicines that address serious diseases. Headquartered in Boston, Massachusetts, PureTech Health specializes in modulating the adaptive human system to create transformative treatments.
The company's core business is focused on discovering and advancing highly differentiated medicines aimed at a wide range of devastating conditions. These include inflammatory, fibrotic, and immunological diseases, as well as intractable cancers, lymphatic and gastrointestinal disorders, and neurological and neuropsychological issues. PureTech Health operates through three key segments: Wholly-Owned Programs, Controlled Founded Entities, and Parent Companies & Others.
Recent Achievements
PureTech Health boasts a robust pipeline of advanced programs that are at the post-human proof of concept stage, targeting some of the most pressing healthcare needs globally. The company's innovative approach has resulted in numerous partnerships and collaborations with leading research institutions and other biopharma entities.
Current Projects
Currently, PureTech Health is involved in several groundbreaking projects aimed at developing treatments that can significantly improve patient outcomes. These projects leverage the company's expertise in modulating the adaptive human system to create therapies that are not only effective but also highly differentiated from existing treatments.
Financial Condition
PureTech Health's financial condition remains strong, supported by a diverse portfolio of wholly-owned programs and controlled founded entities. The company's strategic investments and collaborations have positioned it well to continue driving innovation in the biopharma space.
Partnerships and Collaborations
Collaboration is at the heart of PureTech Health's strategy. The company has established numerous partnerships with top-tier research institutions and other biopharma companies to accelerate the development and commercialization of its innovative therapies.
Products
PureTech Health's product portfolio includes a range of medicines designed to address some of the most challenging diseases. These products are developed with a focus on significantly improving the quality of life for patients.
PureTech Health (LSE:PRTC) announced that its Founded Entity, Sonde Health, has raised $19.25 million in a Series B funding round. This capital will support Sonde's efforts in enhancing its vocal biomarker platform for health monitoring across multiple conditions like asthma and mental health issues. With a total of $35.25 million raised to date, Sonde aims to expand its commercial growth, new health condition applications, and geographical reach, capitalizing on its vast voice dataset of over 1.2 million samples.
PureTech Health has announced the nomination of LYT-310, an oral cannabidiol (CBD) prodrug developed from the Glyph™ platform. LYT-310 shows a three to fourfold increase in oral bioavailability compared to unmodified CBD, which could enhance its therapeutic application across various age groups and indications, including epilepsy. Clinical studies are expected to commence in Q4 2023. This advancement builds on the company's Glyph platform, aimed at improving the oral administration of therapeutics with limited bioavailability.
PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) announced participation in two investor conferences. Management members will engage in fireside chats at the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 1:30 p.m. EST, and the Evercore ISI 5th Annual HealthCONx Conference on November 30, 2022, at 8:50 a.m. EST. The webcasts of these events will be accessible on their investor site. PureTech is focused on innovative biotherapeutics aimed at transforming treatment for serious diseases.
PureTech Health plc (LSE:PRTC, Nasdaq:PRTC) has announced that its CEO, Daphne Zohar, and CMO, Julie Krop, will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2022, at 3:50 PM GMT / 10:50 AM EST. The event will be webcasted, and attendees can access the presentation via the company’s investor relations website. PureTech is focused on innovative therapies to transform treatment for serious diseases, boasting a pipeline of 27 therapeutic candidates, including some with FDA clearance.
Vedanta Biosciences, a clinical-stage biopharmaceutical company, announced that Bernat Olle, CEO, will present at the 9th International Human Microbiome Consortium Congress in Kobe, Japan from November 8-10, 2022. The presentation, titled Development of a Defined Bacterial Consortium for the Prevention of Recurrent Clostridioides Difficile Infection, will showcase Phase 2 results of VE303, a therapeutic candidate for preventing recurrent Clostridioides difficile infection, which showed a 31.7% absolute risk reduction in recurrence compared to placebo.
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced participation in the Credit Suisse 31st Annual Healthcare Conference on November 8, 2022, at 12:50pm PST / 3:50pm EST. Executives Bharatt Chowrira, Ph.D., J.D., and Julie Krop, M.D., will engage in a fireside chat. The event will be webcast at investors.puretechhealth.com. PureTech is focused on innovative biotherapeutics, boasting a diverse pipeline of 27 therapeutic candidates, including FDA-cleared products.
PureTech Health plc (LSE:PRTC, Nasdaq:PRTC) has announced that its CEO, Daphne Zohar, and CMO, Julie Krop, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York City on September 14, 2022, at 2:05 PM EDT. The event will be available via webcast at investors.puretechhealth.com. PureTech continues to advance its extensive pipeline of 27 therapeutics, with some achieving FDA clearance and European marketing authorization.
PureTech Health announced that data from a Phase 1 crossover trial of LYT-100 indicates improved tolerability compared to pirfenidone, supporting dose selection for the Phase 2 trial in patients with idiopathic pulmonary fibrosis (IPF). The Phase 1 trial showed a 50% reduction in gastrointestinal adverse events and a 45% reduction in nervous system treatment-emergent adverse events. The Phase 2 trial, aimed at establishing safety and efficacy, initiated in June 2022. LYT-100, a deuterated form of pirfenidone, is expected to improve patient compliance and outcomes.
PureTech Health plc announces a multi-year partnership with Koye Pharmaceuticals to develop a vocal biomarker for chronic obstructive pulmonary disease (COPD) in India. This collaboration represents Sonde Health's first agreement with a pharmaceutical firm. Utilizing Sonde's vocal biomarker platform, the aim is to enhance monitoring and treatment of COPD patients through voice technology. COPD is a significant health issue in India, accounting for 13% of deaths. The partnership seeks to leverage advanced technology to improve patient outcomes.
PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) is set to announce its half-yearly results for the six months ending June 30, 2022, on August 25, 2022. The Company will host a presentation and conference call for analysts and shareholders at 9:00 am EDT. PureTech is focused on developing innovative therapeutics for serious diseases, boasting a diverse pipeline of 27 therapeutic candidates, including two with FDA clearance and European marketing authorization.
FAQ
What is the current stock price of Puretech Health (PRTC)?
What is the market cap of Puretech Health (PRTC)?
What does PureTech Health plc do?
What are the main focus areas of PureTech Health's research?
What are the key segments PureTech Health operates in?
What are some recent achievements of PureTech Health?
What kind of products does PureTech Health offer?
What is the financial condition of PureTech Health?
Where is PureTech Health headquartered?
How does PureTech Health collaborate with other entities?
What makes PureTech Health's treatments unique?
What are the current projects at PureTech Health?
